Literature DB >> 28529563

Role of NKG2D in cytokine-induced killer cells against lung cancer.

Xiaowei Yin1, Xuzhang Lu2, Zhang Xiuwen2, Zhou Min3, Rong Xiao2, Zhengdao Mao1, Qian Zhang1.   

Abstract

It has been previously demonstrated that cytokine-induced killer (CIK) cells possess potent cytotoxicity against various cancer cells, including lung cancer cells. However, the mechanism by which CIK cells recognize lung cancer cells has not been understood. The interaction between killer cell lectin like receptor K1 (NKG2D) receptor and NKG2D ligands was demonstrated to serve an important role in target cell killing by natural killer cells. The present study investigated whether NKG2D receptor and NKG2D ligand interactions are involved in the CIK-directed killing of lung cancer cells. The expression of MICA and ULBP2 was detected in tumor and healthy tissue samples. The expression of MICA and ULBP2 in tumor tissue samples was higher compared with that in the healthy control tissue. The expression of NKG2D ligands was analyzed in A549 and Q56 cells through reverse transcription-quantitative polymerase chain reaction and flow cytometry. The results demonstrated that the lung cancer cell lines markedly expressed the NKG2D ligands. Furthermore, NKG2D ligand-expressing lung cancer cells were targeted by CIK cells, which was partially blocked by treating CIK cells with an antibody against NKG2D. The data of the current study has demonstrated that the NKG2D-NKG2D ligand interaction serves an essential role in mediating lung cancer cell killing by CIK cells.

Entities:  

Keywords:  MICA/B; NKG2D ligand; cytokine-induced killer cells; lung cancer

Year:  2017        PMID: 28529563      PMCID: PMC5431552          DOI: 10.3892/ol.2017.5800

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  24 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  The role of the NKG2D receptor for tumor immunity.

Authors:  Jérôme D Coudert; Werner Held
Journal:  Semin Cancer Biol       Date:  2006-07-08       Impact factor: 15.707

Review 3.  Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.

Authors:  Giulia Mesiano; Maja Todorovic; Loretta Gammaitoni; Valeria Leuci; Lidia Giraudo Diego; Fabrizio Carnevale-Schianca; Franca Fagioli; Wanda Piacibello; Massimo Aglietta; Dario Sangiolo
Journal:  Expert Opin Biol Ther       Date:  2012-04-14       Impact factor: 4.388

4.  Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

Authors:  Robert Jotte; Paul Conkling; Craig Reynolds; Matthew D Galsky; Leonard Klein; James F Fitzgibbons; Richard McNally; Markus F Renschler; Jennifer W Oliver
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

5.  Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the NKG2D ligand MICA.

Authors:  Mercedes Kloss; Patrice Decker; Katrin M Baltz; Tina Baessler; Gundram Jung; Hans-Georg Rammensee; Alexander Steinle; Matthias Krusch; Helmut R Salih
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

6.  Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.

Authors:  N Kato; J Tanaka; J Sugita; T Toubai; Y Miura; M Ibata; Y Syono; S Ota; T Kondo; M Asaka; M Imamura
Journal:  Leukemia       Date:  2007-07-12       Impact factor: 11.528

7.  MICA/NKG2D-mediated immunogene therapy of experimental gliomas.

Authors:  Manuel A Friese; Michael Platten; Stefan Z Lutz; Ulrike Naumann; Steffen Aulwurm; Felix Bischof; Hans-Jörg Bühring; Johannes Dichgans; Hans-Georg Rammensee; Alexander Steinle; Michael Weller
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 9.  Regulation of immune cell function and differentiation by the NKG2D receptor.

Authors:  Biljana Zafirova; Felix M Wensveen; Maja Gulin; Bojan Polić
Journal:  Cell Mol Life Sci       Date:  2011-09-06       Impact factor: 9.261

Review 10.  Regulation of ligands for the activating receptor NKG2D.

Authors:  Anita R Mistry; Chris A O'Callaghan
Journal:  Immunology       Date:  2007-08       Impact factor: 7.397

View more
  4 in total

Review 1.  Sensing Bacterial-Induced DNA Damaging Effects via Natural Killer Group 2 Member D Immune Receptor: From Dysbiosis to Autoimmunity and Carcinogenesis.

Authors:  J Luis Espinoza; Mika Minami
Journal:  Front Immunol       Date:  2018-01-25       Impact factor: 7.561

2.  Identification of an Immune-Related Risk Signature Correlates With Immunophenotype and Predicts Anti-PD-L1 Efficacy of Urothelial Cancer.

Authors:  Pengju Li; Shihui Hao; Yongkang Ye; Jinhuan Wei; Yiming Tang; Lei Tan; Zhuangyao Liao; Mingxiao Zhang; Jiaying Li; Chengpeng Gui; Jiefei Xiao; Yong Huang; Xu Chen; Jiazheng Cao; Junhang Luo; Wei Chen
Journal:  Front Cell Dev Biol       Date:  2021-03-18

3.  MG132 selectively upregulates MICB through the DNA damage response pathway in A549 cells.

Authors:  Dan Luo; Xi-Wen Dong; Bing Yan; Mei Liu; Tian-Hui Xue; Hui Liu; Jun-Hao You; Fang Li; Zi-Ling Wang; Zhi-Nan Chen
Journal:  Mol Med Rep       Date:  2018-11-20       Impact factor: 2.952

4.  NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.

Authors:  Xiaolong Wu; Amit Sharma; Johannes Oldenburg; Hans Weiher; Markus Essler; Dirk Skowasch; Ingo G H Schmidt-Wolf
Journal:  Front Immunol       Date:  2021-10-07       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.